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Nations Development Programme), 
and now also involves several other 
international organisations. MFF 
focuses on the countries worst hit by 
the 2004 tsunami, i.e. India, Indonesia, 
Maldives, Seychelles, Sri Lanka,  
and Thailand.
While highlighting mangroves as an 
important flagship ecosystem of its 
efforts in the region, the MFF is also 
looking at the conservation of other 
features, including coral reefs and 
estuaries. In the Indian Ocean region, 
even more than in Kenya, mangroves 
are literally at the front line of the 
battle against consequences of 
climate change, but first we will have 
to find efficient ways of protecting 
the mangroves to help them to 
protect us.
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web 
page at www.michaelgross.co.uk
The research aims to quantify 
the carbon storage capacity of 
mangroves and to investigate how 
local communities can best create and 
maintain mangrove plantations, which 
they can exploit as a sustainable 
source of timber. Aviva employees will 
be able to gain first-hand experience 
by working as volunteer helpers in the 
research project. Louella Eastman, 
Aviva’s Corporate Responsibility 
Director, commented: “As an insurer 
we understand only too well the 
human and economic cost of floods, 
storms and extreme weather. This 
research supports our commitment  
to provide carbon finance in  
Africa — something we believe is 
urgently needed.”
Meanwhile, in the Indian Ocean 
region, another initiative is aiming to 
promote the protection of mangroves. 
Mangroves for the Future (MFF) was 
initiated by IUCN and UNDP (United 
Expanding: A project in Kenya is extending mangrove forests along its coast. (Photo: 
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What turned you on to biology? My 
early interests were more in chemistry 
and biochemistry than biology. But at 
an early age I was fascinated by the 
ability of plants to capture photons 
and use them as energy sources 
to build molecules and to perform 
complex tasks. I remember a high 
school biology experiment in which 
we used wax to seal the stem of a 
small branch from a tree into a water-
filled glass tube and then inserted 
the tube into a pool of mercury. 
When placed in bright sunlight, the 
mercury was pulled up the tube. Of 
course, this mysterious conversion 
of photons into mechanical work 
was never adequately explained in 
my 1964 biology course, but it got 
me thinking about the conversion of 
light into energy, as well as osmosis 
and the maintenance of ion gradients 
across membranes, ideas that would 
dominate my early research.
Do you have a favourite paper? 
Yes: Peter Mitchell’s 1961 paper 
‘Coupling of phosphorylation to 
electron and hydrogen transfer by a 
chemi-osmotic type of mechanism’ 
(Nature 191, 144–148). The Holy Grail 
of metabolism in the 1950s and 1960s 
was understanding how mitochondria 
synthesize ATP by oxidative 
metabolism. The prevailing view was 
that oxidation of some component of 
the Krebs cycle would be coupled to 
formation of a high-energy phosphate 
bond on a protein or small molecule 
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to ADP to generate ATP. Mitchell 
noticed that addition of oxygen to 
mitochondria resulted in extrusion 
of protons from the mitochondria, 
and came up with the novel idea that 
the proton gradient generated by 
oxidation of Krebs cycle components 
could be used to dehydrate water 
from ADP and phosphate bound 
at the catalytic site of a membrane 
imbedded enzyme, resulting in ATP 
synthesis. No examples were then 
known of coupling of the chemical 
energy of ATP synthesis or hydrolysis 
to ion flow across a membrane, so this 
was a radical concept. 
Mitchell got the details wrong 
(the coupling to the proton gradient 
is much more indirect than he 
proposed), but the concept was 
correct and it stimulated other 
luminaries in the field such as Efraim 
Racker, Andre Jagendorf, Paul 
Boyer and John Walker to tackle and 
solve the biochemical mechanism. 
I remember well the time when 
Mitchell visited Cornell and my Ph.D. 
advisor, Gordon Hammes, invited 
Mitchell and Racker to his office 
and asked me to present my work 
on characterization of ATP and ADP 
binding sites on the ATP synthase. 
The chemi-osmotic model was still 
controversial at that time (1973) and 
Mitchell and Racker got into major 
debates about the interpretation of 
every detail of my data. I hardly got a 
word in, but it was great fun.
What has been your biggest 
mistake in research? I can think of 
two major mistakes. As a postdoctoral 
fellow, I published a paper proposing 
an activation-dependent shut-off 
mechanism for the enzyme Na+, K+-
ATPase. When I added ATP to the 
enzyme in the presence of Na+ and 
K+, it began to hydrolyse the ATP as 
expected, but within  
10 minutes the enzyme turned off, 
even under conditions where the 
product, ADP, was converted back to 
ATP to prevent product accumulation. 
At about the time the paper was 
published, I discovered that this was 
due to a contaminant in commercial 
ATP. I furiously worked to identify 
the contaminate and found that it 
was vanadate. This led to a second 
paper showing that vanadate is a nM 
inhibitor of Na+, K+-ATPase, acting 
as a transition state analog of the 
phospho-enzyme intermediate (Cantley et al. (1977), J. Biol. Chem. 252, 7421). 
This was one of my most highly cited 
papers, as it explained a lot of artefacts 
from the use of commercial ATP, and 
led to the widespread use of vanadate 
as an inhibitor of enzymes with 
phospho-protein intermediates, such 
as phospho-tyrosine phosphatases. 
Sigma Chemical Company quickly 
changed their process for ATP 
purification to get rid of the vanadate. I 
managed to get a job offer at Harvard.
A second major mistake 
was the assumption that the 
phosphatidylinositol kinase activity 
that we found co-purifying with 
pp60v-src was carried out by the same 
catalytic site as the tyrosine kinase 
activity (Sugimoto et al., (1984), Proc. 
Natl. Acad. Sci. USA 81, 2117). The 
argument for this conclusion was that 
pp60v-src mutations that inactivated 
the tyrosine kinase also inactivated 
the phosphatidylinositol kinase 
activity. In addition, the small molecule 
quercetin inhibited both activities at 
similar concentrations. A year later, 
in collaboration with Tom Roberts 
and Brian Schaffhausen, we showed 
that the phosphatidylinositol kinase 
and tyrosine kinase activities could 
be separated (Whitman et al. (1985), 
Nature 315, 239). In our attempts to 
understand how we had originally 
reached the wrong conclusion, we 
found that the phosphatidylinositol 
kinase only bound to tyrosine kinases 
when they were activated, explaining 
why catalytically inactive pp60v-src 
lacked phosphatidylinositol kinase 
activity. We went on to show that 
this enzyme phosphorylates a site 
on the inositol ring that had not been 
previously observed, thus resulting 
in discovery of phosphoinositide 
3-kinase (PI 3-kinase). Ironically, 
after we purified PI 3-kinase, we 
found it can autophosphorylate on 
serine, so a single catalytic site can 
phosphorylate both lipids and proteins. 
Quercetin became the starting point 
for developing the PI 3-kinase inhibitor 
LY294002 by Lilly Pharmaceuticals.
Both mistakes caused me great 
anxiety at the time, but also spurred 
me to get to the bottom of the 
problem that had led me astray. In the 
end, they resulted in more interesting 
conclusions than I had imagined. I 
guess the lesson is that if you make 
a mistake, you should do all possible 
to correct it and chances are you will 
discover something important in the 
process.What is your greatest ambition? At 
this point in my career, I would like to 
see the knowledge base that has come 
out of decades of research into signal 
transduction and metabolism applied 
to solve diseases. The tremendous 
advances in genome sequencing have 
shed light on the molecular basis of 
many diseases and it has often been 
possible to genetically engineer mice 
or other animals to replicate the events 
that cause the human disease. Many 
of the nodes in the metabolic and 
signalling networks that are perturbed 
are druggable enzymes or receptors 
and pharmaceutical companies have 
begun to deliver investigational drugs 
with pharmaceutical and safety profiles 
that allow use in humans and in the 
animal disease models. We have an 
unprecedented opportunity for clinical 
research with therapies that directly 
target the events known to cause the 
diseases. And we have the opportunity 
to test hypotheses in diverse animal 
models that mirror the diversity in the 
human disease, and thereby accelerate 
the development of personalized 
therapies. We now know that these 
diseases have been difficult to cure 
because they have diverse origins and 
that no single therapy will work for all. 
This type of research requires teams 
from pharmaceutical companies, basic 
research institutes and clinical research 
institutes that have wide ranges of 
expertise. My ambition is to work 
with these teams to accelerate the 
application of the knowledge that we 
have of the molecular origins of these 
diseases to develop cures.
If you knew what you know earlier 
on, would you still pursue the same 
career path? Absolutely. I was a 
chemistry major in college and got my 
PhD in biophysical chemistry. I never 
took a biology course, but as I began 
to pursue my interests in enzymes 
associated with cell membranes I found 
myself more and more absorbed in the 
biology. Forty years ago, I would have 
never imagined I would get excited 
about designing a clinical trial. Yet I feel 
my background in organic chemistry 
and biochemistry was far more useful 
in preparing me for the complexity of 
biology than anything I would have 
learned in a biology class 40 years ago.
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